Interestingly, these gene fusions were mutually exclusive with JAK1/STAT3 mutations, suggesting convergent pathogenetic mechanisms and therapeutic targets for ALK negative ALCL (Figure 1). This evidence concerns the gene JAK1 and anaplastic large cell lymphoma.